Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
As of close of business last night, Thermo Fisher Scientific Inc’s stock clocked out at $448.94, down -3.75% from its previous closing price of $466.42. In other words, the price has decreased by -$3.75 from its previous closing price. On the day, 2.54 million shares were traded. TMO stock price reached its highest trading level at $465.61 during the session, while it also had its lowest trading level at $446.28.
Ratios:
To gain a deeper understanding of TMO’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 26.52 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 27.48. For the most recent quarter (mrq), Quick Ratio is recorded 1.50 and its Current Ratio is at 1.93. In the meantime, Its Debt-to-Equity ratio is 0.70 whereas as Long-Term Debt/Eq ratio is at 0.65.
On July 11, 2025, Scotiabank Upgraded its rating to Sector Outperform which previously was Sector Perform but kept the price unchanged to $590.
UBS Downgraded its Buy to Neutral on July 09, 2025, while the target price for the stock was maintained at $460.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 06 ’25 when CASPER MARC N bought 10,000 shares for $451.82 per share.
Pettiti Gianluca sold 400 shares of TMO for $191,992 on Jul 25 ’25. The Executive Vice President now owns 22,367 shares after completing the transaction at $479.98 per share. On Jul 25 ’25, another insider, Pettiti Gianluca, who serves as the Officer of the company, bought 400 shares for $479.98 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TMO now has a Market Capitalization of 176125902848 and an Enterprise Value of 198862192640. As of this moment, Thermo’s Price-to-Earnings (P/E) ratio for their current fiscal year is 25.98, and their Forward P/E ratio for the next fiscal year is 18.41. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.62. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.92 while its Price-to-Book (P/B) ratio in mrq is 3.36. Its current Enterprise Value per Revenue stands at 4.602 whereas that against EBITDA is 18.384.
Stock Price History:
The Beta on a monthly basis for TMO is 0.76, which has changed by -0.25181657 over the last 52 weeks, in comparison to a change of 0.19283521 over the same period for the S&P500. Over the past 52 weeks, TMO has reached a high of $627.88, while it has fallen to a 52-week low of $385.46. The 50-Day Moving Average of the stock is 5.81%, while the 200-Day Moving Average is calculated to be -8.30%.
Shares Statistics:
It appears that TMO traded 2.89M shares on average per day over the past three months and 3239460 shares per day over the past ten days. A total of 377.61M shares are outstanding, with a floating share count of 376.98M. Insiders hold about 0.17% of the company’s shares, while institutions hold 91.20% stake in the company. Shares short for TMO as of 1752537600 were 3830421 with a Short Ratio of 1.32, compared to 1749772800 on 4909976. Therefore, it implies a Short% of Shares Outstanding of 3830421 and a Short% of Float of 1.0199999.
Dividends & Splits
With its trailing 12-month dividend rate of 1.64, TMO has a forward annual dividend rate of 1.64. Against a Trailing Annual Dividend Yield of 0.0035161441The stock’s 5-year Average Dividend Yield is 0.23. The current Payout Ratio is 9.43% for TMO, which recently paid a dividend on 2025-06-13 with an ex-dividend date of 2025-09-15. Stock splits for the company last occurred on 1996-06-06 when the company split stock in a 3:2 ratio.
Earnings Estimates
A comprehensive evaluation of Thermo Fisher Scientific Inc (TMO) is underway, with the input of 21.0 analysts contributing to its current rating.The consensus estimate for the next quarter is $6.52, with high estimates of $6.93 and low estimates of $6.22.
Analysts are recommending an EPS of between $22.62 and $22.29 for the fiscal current year, implying an average EPS of $22.5. EPS for the following year is $24.45, with 28.0 analysts recommending between $25.87 and $23.5.
Revenue Estimates
In the current quarter, 18 analysts expect revenue to total $10.9B. It ranges from a high estimate of $11B to a low estimate of $10.85B. As of the current estimate, Thermo Fisher Scientific Inc’s year-ago sales were $10.6BFor the next quarter, 18 analysts are estimating revenue of $11.77B. There is a high estimate of $11.95B for the next quarter, whereas the lowest estimate is $11.61B.
A total of 25 analysts have provided revenue estimates for TMO’s current fiscal year. The highest revenue estimate was $44.06B, while the lowest revenue estimate was $43.7B, resulting in an average revenue estimate of $43.88B. In the same quarter a year ago, actual revenue was $42.88BBased on 26 analysts’ estimates, the company’s revenue will be $45.96B in the next fiscal year. The high estimate is $47.58B and the low estimate is $45.01B.
